# Aether Financial Model

Synthetic biology platform that builds searchable protein indexes to engineer novel molecular assemblers for high-value industrial products.

- Canonical: https://finamodel.com/startups/aether
- Excel download: https://finamodel.com/startup-models/aether.xlsx
- Category: Crypto/Web3
- Model type: Unit-economics / DTC
- Funding round: Series A
- Funding: $49M
- Founded: 2023
- Geography: US-focused (PFAS in US drinking water, domestic lithium reserves cited). [DECK slides 18, 20]
- Customer: B2B

## About the company

Aether uses high-throughput protein screening to create empirical protein-reaction indexes and identify patentable biocatalytic reactions. Its miniaturised platform can screen more than 20,000 samples daily per laser, detect over 10,000 reactions per screen, and claims lower cost than comparable technologies.

Three product lines address industrial problems: PFAS degradation for water and soil, proteins for ultra-high-performance polymers, and metal binding for lithium extraction. Aether has identified leads in defluorination, antiviral manufacturing, and aramid polymerisation; one optimisation programme achieved a 64x yield improvement and 190x enantioselectivity improvement.

The financial model should treat each product line as a separate R&D portfolio with milestone timing, programme cost, and commercial route. PFAS partnerships may produce co-development milestones and royalties, materials licensing follows MVP validation, and metals requires a licensing-versus-integration choice. Start with three active programmes, a $49 million raise, and quarterly cash runway.

## What's included

- 5-year monthly revenue build with stage-appropriate growth assumptions
- Full P&L, headcount plan, and operating-expense schedule
- Cash-flow statement, runway, and burn-rate tracking
- Valuation via exit multiple with a DCF cross-check
- Returns analysis with MOIC and IRR
- Unit economics including CAC, LTV, payback, and cohort retention

## Product & value proposition

Aether has built a proprietary high-throughput protein screening platform that:
- Runs miniaturised enzymatic experiments on 1536-well micro-plates.
- Uses acoustic/piezoelectric printers to print thousands of molecules and test proteins at scale.
- Reads reactions via UV-laser mass spectrometry (MALDI-like) on metal chips.
- Screens >20,000 samples/day per laser (20× faster than state of the art).
- Detects >10,000 different reactions per screen.
- Costs up to 10× less per sample and 50× less CapEx than comparable tech.

The platform generates "protein indexes" - empirically tested protein-reaction combination databases - enabling identification of novel biocatalytic reactions (patentable IP). These reactions are then optimised to industrial specs using multi-parametric algorithms.

Three active product lines:
1. Defluorination proteins to degrade PFAS in drinking water / soil.
2. Aramidase/polymerase proteins to manufacture high-complexity ultra-high-performance polymers.
3. Metal-binding proteins to extract strategic metals (lithium) from previously inaccessible brines.

## Market

Per product line (slide 17 image confirmed):
- Product Line 1 (PFAS / defluorination): TAM $40bn
- Product Line 2 (ultra-high performance materials / HCP polymers): TAM >$20bn
- Product Line 3 (metal extraction / lithium): TAM $5bn
- Combined stated TAM: >$65bn

## Revenue model

Three distinct go-to-market / monetisation strategies by product line:

| Product Line | Revenue mechanism |
| -- | -- |
| 1: PFAS defluorination | Co-development partnerships with PFAS filtering/concentration companies serving municipal water utilities and soil remediation. Revenue likely milestone payments + royalties / licensing fees. |
| 2: Ultra-high performance materials | Build MVPs to validate specs → license products and manufacturing process to advanced materials manufacturers. |
| 3: Metal extraction (lithium) | Build pilot-scale refineries to validate cost and generalisability → then either license or vertically integrate depending on metal and margins. |

Platform economics: standardised expression system and biocatalysis (not fermentation) allows fast, low-risk process scale-up. Stated capacity: 5+ new product lines started per year.

## Traction & metrics

- Protein indexing: demonstrated capability to screen >30,000 molecules against individual proteins.
- Throughput advantage: >1,000× more functional labels per protein than state-of-the-art screening technologies.
- Product line leads: protein leads identified for defluorination, antiviral manufacturing, and aramid polymerisation - all generating potential novel IP.
- Protein optimisation case study (unnamed protein/substrate): 15 algorithm iterations over 4 months exceeded 6-month targets; demonstrated 64× product yield improvement and 190× enantioselectivity improvement.

## Unit economics

- Platform CapEx: up to 50× lower CapEx than comparable technology.
- Per-sample cost: up to 10× lower than alternatives through miniaturisation.
- Industry benchmark for drug/molecule development: companies spend 3+ years and $15M+ before attempting to scale manufacturing.
- Aether claims to be able to start 5+ product lines per year and fail-fast / iterate rapidly, implying materially lower per-program cost (specific number not given).

## Competition / moat

Competitive advantages stated:
- Index size: 1,000× more protein-reaction combinations tested than conventional technologies.
- Hypothesis-free screening: detects >10,000 reaction types per screen vs targeted assays used by competitors.
- IP moat: every indexed novel reaction type is patentable and owned by Aether.
- Reaction-first approach: derisk product lines early by mining indexes before committing to product development.
- Platform selectivity criteria: only pursues applications where Aether's proteins are strictly necessary for the final product (not marginal improvements), maximising value capture.

## Team & funding ask / use of funds

- Funding ask: $49M
- Use of funds:
  1. Build out product line(s).
  2. Prototype Aether's second-generation technology.
  3. Build out Aether's executive team.

---

## Recommended financial model

- **Archetype + why:** Multi-product-line deep-tech / platform R&D model with staged revenue recognition (milestone + licensing). This is not a recurring SaaS or DTC model - revenue arrives as lumpy partnership milestones, then licensing royalties once products scale. Best archetype: **platform R&D + licensing P&L**, structured as a project-portfolio model with one tab per product line. Secondary output: a 3-statement model once the first product line is commercially active.

- **Forecast horizon & granularity:** 5–7 years, quarterly for years 1–2, annual thereafter. Early years are spend-dominated; revenue begins in year 2–3 as the first partnership deal closes.

- **Key drivers & assumptions:**

| Driver | Value |
| -- | -- |
| Active product lines at raise close | 3 |
| New product lines started per year | 5+ |
| Time to first partnership revenue (PL1 PFAS) | 12–18 months post-close |
| Time to licensing revenue (PL2 materials) | 24–36 months |
| Time to pilot revenue / licensing (PL3 metals) | 36–48 months |
| First partnership deal size (milestone + royalty) | $5–20M upfront, royalty TBD |
| Licensing royalty rate (PL2, PL3) | 3–8% of product revenue |
| Per-program R&D cost (Aether) | $2–5M/year |
| Headcount growth (R&D + BD) | 10–20 FTE/year |
| Average FTE cost (US deep tech) | $180–220k fully loaded |
| Lab CapEx (platform build-out) | $5–15M in year 1 |
| Gross margin on licensing revenue | 70–85% |
| Gross margin on co-development / milestone | 40–60% |
| PFAS TAM (PL1) | $40bn |
| Materials TAM (PL2) | >$20bn |
| Metals TAM (PL3) | $5bn |
| SOM penetration at year 5 | 0.1–0.5% of relevant TAM per line |
| Raise size | $49M |

- **Scenarios (Base / Bull / Bear - which variables flex):**
  - **Bear:** PL1 partnership delayed to month 24; only 1 deal closed by year 5; per-program costs run 30% over; licensing royalties at lower end (3%).
  - **Base:** PL1 deal in month 18; PL2 licensing in year 3; $49M capital is sufficient; 2–3 partnerships signed by year 5.
  - **Bull:** PL1 deal closes in month 12; PL2 and PL3 partnerships sign concurrently; Aether vertically integrates PL3 metals at year 4 capturing full margin; 5+ product lines generating pipeline value by year 5.

- **Required sheets / outputs:**
  1. **Assumptions** - all inputs centrally controlled
  2. **Product Line 1 (PFAS)** - timeline, milestones, partnership revenue, R&D opex
  3. **Product Line 2 (Materials)** - MVP timeline, licensing revenue ramp
  4. **Product Line 3 (Metals)** - pilot capex, licensing vs vertical integration toggle
  5. **Platform Opex** - headcount, lab costs, G&A, CapEx
  6. **Consolidated P&L** - revenue, gross profit, EBITDA, net burn
  7. **Cash / Runway** - $49M starting cash, quarterly burn, runway to break-even or next raise
  8. **Sensitivity** - runway vs deal timing; per-program cost vs deal size
  9. **Dashboard** - KPI summary (cash runway, active programs, cumulative revenue, burn rate)

## Frequently asked questions

### Is the Aether financial model free?

Yes. The Aether model is a free Excel download with live formulas.

### Can I change the assumptions?

Yes. The workbook is editable and its live formulas recalculate when assumptions change.